01 Oct 2012, BioSpectrum Bureau , BioSpectrum
Singapore: Eisai announced that the Eisai Group's production management structure will undergo a transformation that will see the group shift from its existing production management structure, which is based on manufacturing sites managed by region, to a new globally integrated unit-based structure organized by product family.
By transitioning to the new structure, Eisai aims to clearly define and assign end-to-end accountability for all products, identify the true needs of patients, and further strengthen its production structure so as to provide products that will deliver optimal patient satisfaction.
In consideration of Eisai's product portfolio and technology strategies, the new structure will comprise five product family-based demand chain units (DCUs) and two core function units (CFUs), with each unit autonomously managing their respective activities. Within each DCU, a 'product champion' will be also assigned to every product. Product Champions will be accountable for all production activities related to their assigned product or products, from procurement of raw materials to production, packaging and distribution, taking ownership of these activities to ensure that each DCU delivers products that provide customer satisfaction.
Meanwhile, the CFUs will carry out functions common across all units, including quality assurance and managing contract manufacturing of products, providing expertise in these areas to support the activities of the DCUs. Additionally, a demand chain headquarters (DCHQ) will be established to carry out strategic planning, organizational and talent management and risk management functions to optimize synergies across the entire EDCS organization while maintaining the autonomy of each individual unit.
Under this new structure, Eisai aims to respond to diversifying customer needs in an era of rapid globalization to provide high-quality medicines at affordable prices and deliver products that create customer joy. In doing so, Eisai will continue to make contributions to increase the benefits provided to patients and their families worldwide